BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-El-Enein M, Bauer G, Reinke P, Renner M, Schneider CK. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med. 2014;20:632-642. [PMID: 25262540 DOI: 10.1016/j.molmed.2014.08.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW. Strategies for Derisking Translational Processes for Biomedical Technologies. Trends Biotechnol 2017;35:100-8. [PMID: 27499276 DOI: 10.1016/j.tibtech.2016.07.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
2 Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M, Suzuki K, Xu R, Hishida T, Chang CJ, Esteban CR, Young J, Izpisua Belmonte JC. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun. 2015;6:6413. [PMID: 25752527 DOI: 10.1038/ncomms7413] [Cited by in Crossref: 204] [Cited by in F6Publishing: 179] [Article Influence: 34.0] [Reference Citation Analysis]
3 Ashmore-Harris C, Iafrate M, Saleem A, Fruhwirth GO. Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells. Mol Ther 2020;28:1392-416. [PMID: 32243834 DOI: 10.1016/j.ymthe.2020.03.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
4 Ciuffi A, Mohammadi P, Golumbeanu M, di Iulio J, Telenti A. Bioinformatics and HIV latency. Curr HIV/AIDS Rep. 2015;12:97-106. [PMID: 25586146 DOI: 10.1007/s11904-014-0240-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
5 Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018;7:676-685. [PMID: 30063299 DOI: 10.1002/sctm.17-0282] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 22.0] [Reference Citation Analysis]
6 Abou-El-Enein M, Bauer G, Reinke P. The business case for cell and gene therapies. Nat Biotechnol. 2014;32:1192-1193. [PMID: 25489833 DOI: 10.1038/nbt.3084] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
7 Riva L, Petrini C. A few ethical issues in translational research for gene and cell therapy. J Transl Med 2019;17:395. [PMID: 31779636 DOI: 10.1186/s12967-019-02154-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
8 Letourneur D, Joyce K, Chauvierre C, Bayon Y, Pandit A. Enabling MedTech Translation in Academia: Redefining Value Proposition with Updated Regulations. Adv Healthc Mater 2021;10:e2001237. [PMID: 32935923 DOI: 10.1002/adhm.202001237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Younan PM, Polacino P, Kowalski JP, Hu SL, Kiem HP. Combinatorial hematopoietic stem cell transplantation and vaccination reduces viral pathogenesis following SHIV89.6P-challenge. Gene Ther 2015;22:1007-12. [PMID: 26355737 DOI: 10.1038/gt.2015.83] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Elsanhoury A, Sanzenbacher R, Reinke P, Abou-El-Enein M. Accelerating Patients' Access to Advanced Therapies in the EU. Mol Ther Methods Clin Dev 2017;7:15-9. [PMID: 28971109 DOI: 10.1016/j.omtm.2017.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
11 Abou-el-enein M, Schneider CK. Deciphering the EU clinical trials regulation. Nat Biotechnol 2016;34:231-3. [DOI: 10.1038/nbt.3492] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
12 Abou-El-Enein M, Bauer G, Medcalf N, Volk HD, Reinke P. Putting a price tag on novel autologous cellular therapies. Cytotherapy. 2016;18:1056-1061. [PMID: 27288308 DOI: 10.1016/j.jcyt.2016.05.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
13 Abou-El-Enein M, Bauer G, Reinke P. Gene therapy: a possible future standard for HIV care. Trends Biotechnol 2015;33:374-6. [PMID: 26088914 DOI: 10.1016/j.tibtech.2015.03.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
14 Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell. 2016;19:293-297. [PMID: 27588746 DOI: 10.1016/j.stem.2016.08.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 18.3] [Reference Citation Analysis]
15 Master Z, Matthews KRW, Abou-El-Enein M. Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports 2021;16:1435-45. [PMID: 34107243 DOI: 10.1016/j.stemcr.2021.05.004] [Reference Citation Analysis]
16 Liao HK, Li M, Martinez Martinez L, Izpisua Belmonte JC. Stem cell, CRISPR and HIV. Cell Cycle 2015;14:1991-2. [PMID: 26039637 DOI: 10.1080/15384101.2015.1046791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Carvalho M, Sepodes B, Martins AP. Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework. Front Med (Lausanne) 2017;4:182. [PMID: 29124055 DOI: 10.3389/fmed.2017.00182] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
18 Dan N; Department of Chemical and Biological Engineering, Drexel University, Philadelphia, PA, 19104, USA. . AIMS Biophysics 2015;2:163-83. [DOI: 10.3934/biophy.2015.2.163] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]